AGC Pharma Chemicals is investing $100-million-plus to expand small-molecule active pharmaceutical ingredient (API) manufacturing, including high-potency API manufacturing. Akihiro Kadokura, CEO, AGC Pharma Chemicals Europe S.L.U., provided an update at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week. 

AGC Pharma Chemicals is a CDMO of small molecules, located in Spain and Japan, and is  increasing its production capacity by 30% to enhance its current API and HAPI capabilities, from gram to ton scale, including the addition of a micronizer. The new facilities will feature new reactors with volumes ranging from 1.5 m³, to 7.5 m³, including HAPI capability, covering a building area of 7,500 m².

The new plant in Barcelona, Spain, will be operational in the second quarter of 2025, alongside the company’s current multi-purpose production lines. The investment amount exceeds $100 million. The company noted it is prepared to install additional lines and incorporate new technologies in the future, based on customer requests, which it can accommodate due to the facility’s modular design.